Simon Rossignol of EvergoldLongevity explains why the longevity economy needs a “Medicine 3.0” interface for the 60+ demographic.
The longevity section of 2026 is a study in paradox. On one side of the “application gap” we see a golden age of higher science: epigenetic programming, senolytic cocktails, and decoding Signs of aging are no longer speculation – they are in human clinical trials. But, on the other side sits the real end user: the 60+ demographic. For this group, the multibillion-dollar promise of cell immortality often feels like “biological steam.”
To transform the longevity industry from an economic engine of scale, we must address this disconnect. We don’t just need better science; we need a better interface. We need Medicine 3.0.
The current lie of the earth: high science, low profits
The current state of the field is dominated by “Medicine 2.0″—a reactive, disease-focused model that has successfully extended life but failed to preserve health. While billions of people go in search of the “longevity pill,” the underlying drivers of chronic disease—sarcopenia, cognitive decline, and metabolic disorders—remain largely unaddressed in the daily lives of the aging population.
Currently, the industry is dealing with “longevity hype”. We’re fascinated by the idea of reversing aging by 20 years, but we struggle to make sure a 70-year-old maintains the stamina he needs to remain independent. This is where the longevity space should rotate. We need to move beyond the molecular and into the functional.
The business opportunity of sarcopenia: undervalued capital
If I were to identify the most undervalued “Longevity Technology” vertical in 2026, it wouldn’t be a new drug; This will protect the muscles. Sarcopenia – age-related loss of muscle mass and function – is the “killer” of the longevity economy. Muscle isn’t just for aesthetics; it is a metabolic organ and a major predictor of all-cause mortality. However, while the market for GLP-1 agonists has exploded, the market for technologies that facilitate high-intensity resistance training in the elderly is still in its infancy. There is a huge commercial opening for specialized “Osteogenic Loading” technology and digital platforms that treat muscle as a fluid asset to be protected in any case.
Moving beyond the molecular and into the functional, in particular on core integrity and muscle healththat is where the industry needs to move.
Biomarkers as consumables: maximal VO₂ change
In Medicine 2.0, biomarkers like VO₂ max were limited to elite sports laboratories or clinical cardiology. In the era of Medicine 3.0, these will become everyday consumer products.
The transition from a laboratory test to an integrated “Biological Age” score is the first step in addressing the implementation gap. By 2030, the most valuable companies for longevity will not be those that sell supplements, but those that sell feedback loops. When a 65-year-old man can see the direct effect of morning exercise on VO₂ max or heart rate variability (HRV) in real time, the “abstract” concept of longevity becomes a “tangible” everyday game.
The Conformity Problem: The Missing Behavioral Link
The greatest failure of high science interventions is not efficacy, but consistency. A protocol that is 99% effective in longevity is 0% effective if the patient cannot perform it.
The longevity space needs to stop acting like a lab and start acting like a behavioral design studio. Medicine 3.0 is an “Enabling” framework. This requires a shift from the “Doctor as Authority” model to the “Human as CEO” model. We need digital interfaces that integrate long-lived protocols into the messy realities of life—accounting for travel, stress, and changing motivations. Without a behavioral interface, the best science in the world is just a shelf.
2030 Cycle Prediction: Centennial Decathlon
As we look to 2030, I predict that the general category will shift towards longevity and concierge health coaches. This is motivated by the concept of the “Medieval Decathlon” – the idea that we should train today for specific physical tasks that we want to perform at 100.
This transition creates a new class of assets: Neurological and physical capital. High net worth individuals are already moving away from traditional wealth management to “Health Management”. Phase 2030 will see the emergence of “Longevity Concierges” who will develop customized protocols with area 2 training, sustainability work and precision pharmacology, all managed through a centralized Medicine 3.0 dashboard.
What should change?
The longevity industry needs to stop selling “eternal” and start selling “function.”
To achieve this, we must:
- Preventive measures: we need a change in insurance and health care accounting that rewards muscle mass maintenance and maximal VO₂ improvement, not just treating their decline.
- Democratization of data: The “black box” of clinical biomarkers needs to be opened. Adults should have their bio information as clear as they have their bank statements.
- Humanizing technology: wearables and long-lived apps must transcend the “Silicon Valley” aesthetic and design for the visual and cognitive needs of the 60+ demographic without being “ageist.”
Closing the gap
The longevity economy is currently built on a foundation of great science, but its upper floors—the actual delivery of health—are still under construction. By adopting the Medicine 3.0 interface, we can bridge the gap between the laboratory chair and the breakfast table.
We don’t just need to add years to life; we have to add the infrastructure of life to those years.
The future of longevity isn’t in the lab in 2050 — it’s in the habits of today’s 65-year-olds.
About Simon Rossignol
Simone Rossinoli is its founder and main writer EvergoldLongevity.coma platform that translates complex biological science into practical longevity strategies. With nearly three decades of experience as a biological researcher, he has spent his career investigating the fundamental mechanisms of life and health.
A graduate of the University of Rome “La Sapienza”, Simone embarked on this new journey in the digital space to bridge the gap between high-level research and society and help readers navigate the science of aging with clarity and evidence-based understanding.
